Helei Hou

<p>Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC</p>

Helei Hou, Kang Qin, Liang Yu et al. · Cancer Management and Research · 2019 · 78 citations · Full text

Medicine, Oncology, Pharmacology +16

Tunicamycin Potentiates Cisplatin Anticancer Efficacy through the DPAGT1/Akt/ABCG2 Pathway in Mouse Xenograft Models of Human Hepatocellular Carcinoma

Helei Hou, Hefen Sun, Ping Lü et al. · Molecular Cancer Therapeutics · 2013 · 63 citations

Medicine, Oncology, Pharmacology +17

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC

Dantong Sun, Yan Zhu, Jingjuan Zhu et al. · Molecular Medicine · 2020 · 44 citations · Full text

Medicine, Oncology, Pharmacology +17

Saikosaponin-d suppresses the expression of cyclooxygenase-2 through the phospho-signal transducer and activator of transcription 3/hypoxia-inducible factor-1α pathway in hepatocellular carcinoma cells

Shuixiang He, Guifang Lu, Helei Hou et al. · Molecular Medicine Reports · 2014 · 37 citations · Full text

Medicine, Oncology, Pharmacology +14

<scp><i>ALK</i></scp>rearrangements as mechanisms of acquired resistance to osimertinib in<scp><i>EGFR</i></scp>mutant non‐small cell lung cancer

Helei Hou, Dantong Sun, Chuantao Zhang et al. · Thoracic Cancer · 2021 · 23 citations · Full text

Medicine, Oncology, Pharmacology +14